We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
DRD2 expression based on <sup>18</sup>F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study.
- Authors
Tang, Hao; Cheng, Yijun; Lou, Xiaohui; Yao, Hong; Xie, Jing; Gu, Weiting; Huang, Xinyun; Liu, Yanting; Lin, Shaojian; Dai, Yuting; Xue, Li; Lin, Xiaozhu; Wu, Zhe Bao
- Abstract
Purpose: The dopamine agonists (DA) have been used widely to treat prolactinomas. However, it is difficult to predict whether the patient will be responsive to DA treatment. Methods: We aimed to investigate whether the in vivo expression of DRD2 based on 18F-fallypride PET/MR could predict the therapeutic effect of DA on prolactinomas. Seven patients with prolactinomas completed 18F-fallypride PET/MR. Among them, three patients underwent surgery and further tumor immunohistochemistry. Imaging findings and immunohistochemical staining were compared with treatment outcomes. Results: 18F-fallypride PET/MR was visually positive in 7 of 7 patients, and DRD2 target specificity could be confirmed by immunohistochemical staining. A significantly lower tracer standard uptake value (SUV) could be detected in the resistant patients (n = 3) than in the sensitive patients (n = 4; SUVmean, 4.67 ± 1.32 vs. 13.57 ± 2.42, p < 0.05). DRD2 expression determined by 18F-fallypride PET/MR corresponded with the DA treatment response. Conclusion: 18F-fallypride PET/MR may be a promising technique for predicting DA response in patients with prolactinoma.
- Publication
Endocrine (1355008X), 2023, Vol 80, Issue 2, p419
- ISSN
1355-008X
- Publication type
Article
- DOI
10.1007/s12020-023-03310-0